Short sellers are heavily targeting small- and mid-cap names, particularly in the biotech sector, where several stocks are carrying short interest above 30%. KalVista Pharmaceuticals (KALV) and ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

Stock Market Today: The Dow Jones index rose as Nvidia shined. Oracle soared and Cathie Wood bought a Warren Buffett stock.

Romanian startups exceeded expectations in 2025, registering an influx of capital and signaling a shift in the local sector.  The growth of last year was backed by international investors such as ...

Hover over macros to see definitions and expansion results Interactive buttons for step-by-step expansion Show numeric values for constant macros Display definition locations ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...

Absci Corp. research and ratings by Barron's. View ABSI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Recursion Pharmaceuticals is a pioneer in AI-powered drug discovery but faces challenges in monetizing its innovations and aligning management's vision with sustainable revenue paths. The company's ...

For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing the ...